Redefining What’s Possible in
Non-Viral Gene Therapy
We’re a clinical-stage biotechnology company advancing a new class of nucleic acid–based therapeutics powered by STELLAR™, our validated, re-dosable, non-viral delivery platform.
Who We Are
A Clinical-Stage Company Leading the Next Wave of Non-Viral Gene Delivery
Copernicus Therapeutics is pushing the boundaries of what gene therapy can achieve. Our lead program for cystic fibrosis has already demonstrated human proof-of-concept — and it’s just the beginning.
With a platform validated in multiple tissues and a Phase 2b-ready asset, we’re advancing therapies with the potential to safely reach more patients, more often, and with fewer limitations than traditional viral vectors.
Key Highlights
Positive Phase I/II Human Data
Multiple FDA Orphan Drug Designations
Phase IIb Trial Designed Based on FDA Guidance
Pipeline Across Rare and High-Impact Diseases
Re-dosable, Non-Immunogenic Delivery
What Drives Us
Solving Unmet Needs with Scalable, Accessible Gene Therapy
Millions of patients live with genetic diseases that current approaches can’t reach — whether due to mutation type, immune barriers, or safety limitations.
We’re building gene therapies that overcome those barriers, expanding access to treatments and enabling a future where durable, repeatable genetic medicine is available to everyone who needs it.
How We Work
Innovation With Purpose
We combine advanced delivery biology with the rigor of a clinical-stage drug developer. Every program we pursue, every partnership we consider, and every technology we build moves us closer to a world where genetic disease has fewer limits — and more solutions.